TherapeuticsMD, Inc. (TXMD)
| Market Cap | 26.87M |
| Revenue (ttm) | 86.42M |
| Net Income (ttm) | -182.05M |
| Shares Out | 8.67M |
| EPS (ttm) | -21.73 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 22,132,203 |
| Open | 2.26 |
| Previous Close | 2.27 |
| Day's Range | 2.24 - 3.35 |
| 52-Week Range | 2.21 - 69.50 |
| Beta | 2.09 |
| Analysts | Buy |
| Price Target | 64.26 (+1,972.9%) |
| Earnings Date | May 16, 2022 |
About TXMD
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008H...
Financial Performance
In 2021, TherapeuticsMD's revenue was $86.95 million, an increase of 34.03% compared to the previous year's $64.87 million. Losses were -$172.42 million, -6.05% less than in 2020.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for TXMD stock is "Buy." The 12-month stock price forecast is 64.26, which is an increase of 1,972.90% from the latest price.
News
Hot Biotech Penny Stocks to Watch as Stocks Enter Bear Market
Are these biotech penny stocks on your watchlist right now? The post Hot Biotech Penny Stocks to Watch as Stocks Enter Bear Market appeared first on Penny Stocks to Buy, Picks, News and Information | P...
Why TherapeuticsMD Shares Are Trading Higher Today
TherapeuticsMD Inc (NASDAQ: TXMD) shares are trading higher after FDA approved the supplemental application, including minor revisions to Annovera's in vitro release testing specification that allowed f...
TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA)...
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ:TXMD) (“TXMD” or the “Company”), an innovative, leading women's healthcare company, today announced the FDA's approval of a supplemental N...
TherapeuticsMD (TXMD) Reports Q1 Loss, Misses Revenue Estimates
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -34.86% and 1.41%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
TherapeuticsMD Announces First Quarter 2022 Financial Results
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women's healthcare company, today reported financial results for the first quarte...
TherapeuticsMD to Report First Quarter 2022 Financial Results on May 16, 2022
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women's healthcare company, today announced that it will report its first quarter...
TherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at ...
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TXMD” or the “Company”) an innovative, leading women's healthcare company, announced today the closing of the divestiture of vit...
Best Penny Stocks To Buy? 5 Explosive Stocks Under $1 To Watch Now
Penny Stocks Under $1 To Watch This Week. The post Best Penny Stocks To Buy?
TherapeuticsMD (TXMD) Reports Q4 Loss, Lags Revenue Estimates
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -50% and 37.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
TherapeuticsMD Announces Fourth Quarter 2021 Financial Results
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women's healthcare company, today reported financial results for the fourth quart...
Why TherapeuticsMD Shares Are Soaring Today
TherapeuticsMD Inc (NASDAQ: TXMD) is trading higher Monday after the company announced it would sell its prescription services business, vitaCare, to GoodRx Holdings Inc (NASDAQ: GDRX). Under terms of t...
Trading Penny Stocks? Top Stock Market News for March 7th, 2022
Here's what you need to know about trading penny stocks on March 7th The post Trading Penny Stocks? Top Stock Market News for March 7th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Infor...
TherapeuticsMD Shares Soars After VitaCare Divestiture In $150M Deal
TherapeuticsMD Inc (NASDAQ: TXMD) has agreed to divest its VitaCare Prescription Services business to GoodRx Holdings Inc (NASDAQ: GDRX) for $150 million. VitaCare is a consumer-focused digital healthca...
TherapeuticsMD Enters Into a Definitive Agreement to Divest vitaCare to GoodRx
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women's healthcare company, today announced that it has entered into a definitive...
TherapeuticsMD to Report Fourth Quarter 2021 Financial Results on March 10, 2022
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women's healthcare company, today announced that it will report its fourth quarte...
3 Penny Stocks To Watch Under $1 That Are Moving Right Now
Looking for penny stocks to buy under $1? Check these three out for your watchlist The post 3 Penny Stocks To Watch Under $1 That Are Moving Right Now appeared first on Penny Stocks to Buy, Picks, News ...
FDA Approves TherapeuticsMD's Low Dose Bijuva
TherapeuticsMD Inc (NASDAQ: TXMD) is trading sharply higher after it announced that the FDA approved a low dose version of Bijuva, an oral hormone therapy to treat women with vasomotor symptoms due to m...
TherapeuticsMD's Birth Control Med Receives FDA Response Letter To Revise Manufacturing Testing Limits
TherapeuticsMD Inc (NASDAQ: TXMD) said that the FDA could not approve revisions to certain manufacturing testing limits for Annovera through the supplemental marketing application previously submitted b...
U.S. Food and Drug Administration (FDA) Responds to Request From TherapeuticsMD to Revise Certain Manufacturing Testi...
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ:TXMD) (“TXMD” or the “Company”), an innovative, leading women's healthcare company, today announced that the FDA determined that it could ...
TherapeuticsMD, Amneal Settle US Patent Litigation For Bijuva
TherapeuticsMD Inc (NASDAQ: TXMD) has settled the previously disclosed U.S. patent litigation for Bijuva with Amneal Pharmaceuticals Inc (NYSE: AMRX). Bijuva is a prescription medicine used to treat vas...
TherapeuticsMD Settles U.S. Patent Litigation with Amneal for BIJUVA® (Estradiol and Progesterone) — Allowing for a M...
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women's healthcare company, today announced the settlement of the previously disclosed U.S. patent litigati...
Recap: TherapeuticsMD Q3 Earnings
TherapeuticsMD (NASDAQ:TXMD) reported its Q3 earnings results on Thursday, November 11, 2021 at 08:00 AM. Here's what investors need to know about the announcement.
TherapeuticsMD Announces Third Quarter 2021 Financial Results
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women's healthcare company, today reported financial results for the third quarte...
TherapeuticsMD Announces Leadership Changes; Appointment of Industry Veteran, Hugh O'Dowd, as Chief Executive Officer
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD) (TXMD or the Company), an innovative, leading women's healthcare company, today announced key leadership changes, including the app...
TherapeuticsMD (TXMD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.